HC Wainwright Raises Dyne Therapeutics (NASDAQ:DYN) Price Target to $48.00

Dyne Therapeutics (NASDAQ:DYN) had its price target increased by HC Wainwright from $36.00 to $48.00 in a research note published on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Dyne Therapeutics’ FY2025 earnings at ($1.41) EPS, FY2026 earnings at $0.23 EPS, FY2027 earnings at $1.40 EPS and FY2028 earnings at $2.97 EPS.

DYN has been the subject of a number of other research reports. Chardan Capital reiterated a buy rating and set a $31.00 target price on shares of Dyne Therapeutics in a research report on Monday, May 6th. Morgan Stanley initiated coverage on shares of Dyne Therapeutics in a research report on Tuesday, April 30th. They set an overweight rating and a $40.00 target price for the company. Stifel Nicolaus increased their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a buy rating in a research report on Wednesday, March 6th. Piper Sandler increased their price objective on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an overweight rating in a report on Wednesday, March 6th. Finally, Oppenheimer reissued an outperform rating and set a $47.00 price objective on shares of Dyne Therapeutics in a report on Monday, May 6th. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $40.78.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $31.53 on Monday. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -7.94 and a beta of 1.00. The firm has a fifty day moving average of $26.96 and a 200-day moving average of $20.43. Dyne Therapeutics has a 52-week low of $6.40 and a 52-week high of $35.98.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.81). On average, sell-side analysts predict that Dyne Therapeutics will post -3.1 earnings per share for the current year.

Insider Activity

In other news, major shareholder Venture Fund Xi L.P. Atlas sold 159,542 shares of the firm’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $22.70, for a total value of $3,621,603.40. Following the transaction, the insider now owns 6,352,562 shares of the company’s stock, valued at approximately $144,203,157.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Venture Fund Xi L.P. Atlas sold 159,542 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $22.70, for a total transaction of $3,621,603.40. Following the transaction, the insider now owns 6,352,562 shares of the company’s stock, valued at approximately $144,203,157.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jason P. Rhodes sold 190,920 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $24.84, for a total transaction of $4,742,452.80. Following the transaction, the director now directly owns 864,487 shares in the company, valued at approximately $21,473,857.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,094,383 shares of company stock valued at $26,724,672. 20.77% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. acquired a new stake in Dyne Therapeutics during the 4th quarter worth approximately $4,988,000. Assenagon Asset Management S.A. increased its holdings in Dyne Therapeutics by 24.5% during the third quarter. Assenagon Asset Management S.A. now owns 721,474 shares of the company’s stock worth $6,464,000 after buying an additional 142,083 shares during the last quarter. Acuta Capital Partners LLC boosted its position in Dyne Therapeutics by 100.7% during the third quarter. Acuta Capital Partners LLC now owns 146,500 shares of the company’s stock worth $1,313,000 after purchasing an additional 73,500 shares during the period. TD Asset Management Inc bought a new position in Dyne Therapeutics during the third quarter worth $206,000. Finally, Profund Advisors LLC boosted its position in Dyne Therapeutics by 9.8% during the third quarter. Profund Advisors LLC now owns 23,793 shares of the company’s stock worth $213,000 after purchasing an additional 2,131 shares during the period. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.